Patent · US Active

Heterocyclic compound as protein kinase inhibitor

US8957102B2 · kind B2 · utility

3Cited by
0References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 28, 2009
Grant dateFeb 17, 2015
Priority date
Expiry dateOct 22, 2031

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are novel heterocyclic compounds useful as anti-cancer drugs by suppressing protein kinase activities of growth factor receptors such as c-Met, pharmaceutical compositions containing the same, and methods for using the compound.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.